Table 4.
Antimicrobial Resistance Rates in all Hospitals
| Multidrug-resistant organism | Number of patients treated for MDRO | Prevalence of MDRO (%, number of patients treated for MDRO on number of patients receiving antimicrobials for therapeutic use (CAI and HAI)) |
|---|---|---|
| MRSA | 29 | 2.7 |
| MRCoNS | 6 | 0.6 |
| VRE | 10 | 0.9 |
| ESBL | 20 | 1.8 |
| 3-ceph | 11 | 1.0 |
| CRE | 0 | |
| ESBL-NF | 2 | 0.2 |
| CR-NF | 2 | 0.2 |
| Other MDRO | 19 | 1.7 |
Abbreviations: 3-ceph 3rd generation cephalosporin resistant Enterobacteriaceae (non-ESBL or ESBL status unknown), CAI community-acquired infection, CRE carbapenem-resistant Enterobacteriaceae, CR-NF carbapenem-resistant non-fermenter Gram-negative bacilli, ESBL bacteria producing extended-spectrum beta-lactamases, ESBL-NF ESBL-producing non-fermenter Gram-negative bacilli, HAI healthcare-associated infection, MDRO multi-drug resistant organism, MRCoNS methicillin-resistant coagulase negative staphylococci, MRSA methicillin-resistant Staphylococcus aureus, VRE Vancomycin-resistant enterococci